CAS: 6975-44-6; Ethyl 4,6-Dihydroxynicotinate

相似化合物

5466-62-6 79398-27-9 70254-52-3

上下游产品

CAS号122-51-0 原甲酸三乙酯 | CAS号105-50-0 丙酮二羧酸二乙酯 | CAS号149-73-5 原甲酸三甲酯 | CAS号108-24-7 乙酸酐 | CAS号570-08-1 瑞吡司特中间体 | CAS号64-19-7 冰醋酸 | CAS号107836-75-9 4,6-二氯烟酰氯 | CAS号405230-82-2 2,5-二氯-4-氨基吡啶 | CAS号40296-46-6 4,6-二氯烟酸乙酯 | CAS号143834-60-0 2,4-二羟基-5-羟甲基吡啶 | CAS号449811-29-4 6-氯-4-(甲基氨基)烟醛 | CAS号181261-73-4 4,5,6-三氯烟酸乙酯 | CAS号24501-21-1 3-硝基吡啶-2,4-二胺 | CAS号28443-69-8 2,3,5-三氯-4-氨基吡啶 | CAS号89282-12-2 2,4-二羟基-3-硝基吡啶 | CAS号846541-71-7 5-氯-4,6-二羟基-3-羧酸乙酯

1,3-丙酮二羧酸二乙酯置于乙酸酐,原甲酸三乙酯,Ammonium Hydroxide体系中,化学反应 3.25H,以72%的收率获得产物4,6-二羟基烟酸乙酯
参考文献:1,6-Naphthyridin-2(1H)-Ones 通过顺序一锅 Suzuki-Miyaura 交叉偶联的差异功能化
标题:1,6-Naphthyridin-2(1H)-Ones 通过顺序一锅 Suzuki-Miyaura 交叉偶联的差异功能化
摘要:7-Chloro-3-Iodo-1-Methyl-1,6-Naphthyridin-2(1H)-One 的实际合成描述了从 2-Chloro-4-(Methylamino)Nicotinaldehyde 开始.然后二卤化合物经历顺序的,位点选择性的 Suzuki-Miyaura 交叉偶联反应,以非常好的收率提供高度官能化的 1,6-萘啶酮.
DOI:10.1002/ejoc.201301631

专利信息

专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.